Loading...
Market
Which drug will be the main competitor to KERENDIA® in the HFmrEF and HFpEF market by end of 2024?
3
Resolution / Starting Odds
Entresto (Novartis) • 25%
Farxiga (AstraZeneca) • 25%
Jardiance (Boehringer Ingelheim) • 25%
Other • 25%
Industry reports and market analysis from firms like IMS Health or IQVIA
Story
Bayer's Finerenone Achieves Primary Endpoint in Phase III HFmrEF and HFpEF Study
Aug 5, 2024, 06:40 AM
Bayer has announced that its Phase III FINEARTS-HF cardiovascular outcomes study investigating KERENDIA® (finerenone) in patients with heart failure with mildly reduced or preserved ejection fraction has achieved its primary endpoint. The study showed that finerenone, a non-steroidal MRA, demonstrated definitive cardiovascular benefits in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF), including reductions in CVd+total HF events. The results are seen as key to unlocking blockbuster sales for the drug. Full results will be presented at the upcoming ESC Congress.
View original story
Similar markets
Semaglutide • 25%
Empagliflozin • 25%
Dapagliflozin • 25%
Other • 25%
Verzenio (abemaciclib) • 25%
Kisqali (ribociclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Sanofi • 25%
AstraZeneca • 25%
Other • 25%
Vutrisiran leads • 25%
Acoramidis leads • 25%
Both have equal market share • 25%
Neither has significant market share • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Bristol-Myers Squibb • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%